Formulation and Specifications: Tablets: 5 mgIndications: Combined with an aromatase inhibitor for patients with locally advanced or metastatic breast cancer that is HR-positive, HER2-negative, postmenopausal, and has recurred or progressed…
Formulation and Specifications: Tablets: 50mg, 100mg, 150mgIndications: Locally advanced or metastatic breast cancer that is HR-positive and HER2-negative: (1) Use in combination with an aromatase inhibitor as initial endocrine therapy…
Formulation and Specifications: Capsules: 75mg, 100mg, 125mgIndications: This product is indicated for hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer: (1) in combination with an aromatase inhibitor as…
Formulation and Specifications: Tablets: 40 mgIndications: Indicated for intensive adjuvant therapy in adult patients with HER2-positive early-stage breast cancer after adjuvant trastuzumab-containing therapy.Key points for rational use:1. HER2 testing is…
Formulation and Specifications: Tablets: 80mg, 160mgIndications: Pyrrolitinib in combination with capecitabine is indicated for the treatment of patients with HER2-positive recurrent or metastatic breast cancer who have not previously received…
Formulation and Specifications: Tablets: 0.25gIndications: Lapatinib in combination with capecitabine is indicated for the treatment of patients with advanced or metastatic breast cancer with HER2 overexpression and prior treatment including…
Formulation and Specifications: Injection: 50mg/stemIndications: This product is indicated for patients with HER2-positive, metastatic breast cancer who have received 1 or more chemotherapy regimens in combination with vincristine.Key Points for…
Formulation and specifications: Injection: 420mg (14ml)/bottleIndications:1. Breast cancer adjuvant therapy: This product is used in combination with trastuzumab and chemotherapy for the adjuvant treatment of HER2-positive early-stage breast cancer patients…
Formulation and Specifications: Injection: 100mg/vial, 160mg/vialIndications: Single agent is indicated for the adjuvant treatment of HER2-positive early-stage breast cancer patients with residual invasive lesions despite receiving paclitaxel-based neoadjuvant therapy in…
Formulation and specifications: Injection: 440mg (20ml)/bottleIndications:1. Recurrent metastatic breast cancer: This product is indicated for HER2-positive metastatic breast cancer. It is used alone for metastatic breast cancer that has received…